Researchers from the Federal University of Kazan (Volga Region) in collaboration with specialists at the Federal Center for Toxicological, Radiation and Biological Safety in Kazan have developed a novel compound derived from terpene alcohols. This new substance is aimed at tackling Candida fungi responsible for thrush, with findings published in Organic and Biomolecular Chemistry.
Candidiasis, commonly known as thrush, presents as sores in the mouth and on the genitalia caused by yeast-like fungi. These organisms are part of the normal, conditionally pathogenic microflora that reside on healthy skin and mucous membranes. Under certain conditions, their population can surge, leading to candidal infections. Standard treatments frequently rely on azole antifungals, which disrupt fungal cell membrane synthesis to kill the organisms. Yet persistent use can lead to resistance, diminishing the effectiveness of these drugs over time.
The newly identified substance belongs to the terpenoid family, a class of plant-derived oxygen-containing compounds. Terpenoids are known to impede fungal growth while enabling easier skin penetration. Unlike azoles, they may not immediately kill fungi but can inhibit their proliferation and potentially transport active molecules deeper into tissues. One terpenoid derivative is already progressing through clinical evaluation and could become a therapeutic option for thrush in the future.
Project leaders emphasize that semi-synthetic terpenoid compounds hold promise for creating antifungal drugs that are biocompatible and sourced from natural materials or their processing products. This approach could lead to safer treatment options with potentially fewer side effects compared to some conventional antifungals, expanding the toolkit available to clinicians managing fungal infections.
Looking ahead, the research team plans to advance toward a comprehensive medication that can be applied to affected skin regions, aiming to improve local treatment outcomes for patients with candidiasis. The investigation continues to explore how terpenoid derivatives can be optimized for efficacy, safety, and ease of use in real-world clinical settings.
In medical observations, discomfort during intercourse has been reported by some individuals with thrush, a symptom that underscores the impact of candidal infections on quality of life. Clinicians note that timely diagnosis and appropriate antifungal therapy are essential to relieve symptoms and prevent recurrence, particularly in populations at higher risk for fungal infections.